Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 5/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.45 |
| ▸ | FAAH | O00519 | 3/20 | 0.44 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL406043 | 0.86 | MTNR1A (0.57) | MTNR1AMTNR1BFAAHP2RX7 | |
| SCHEMBL15478536 | 0.86 | MTNR1A (0.57) | MTNR1AMTNR1BFAAHP2RX7 | |
| SCHEMBL15116647 | 0.82 | ACHE (0.46) | NOTUM | |
| SCHEMBL7332248 | 0.80 | FAAH (0.47) | MTNR1AMTNR1BFAAHGRM7P2RX7 | |
| SCHEMBL762699 | 0.80 | NOTUM (0.46) | MTNR1AMTNR1BNOTUM | |
| SCHEMBL1192966 | 0.78 | FAAH (0.46) | MTNR1AMTNR1BFAAHGRM7P2RX7 | |
| SCHEMBL289302 | 0.78 | AKR1C3 (0.50) | NOTUMFAAHGRM7P2RX7 | |
| SCHEMBL29443025 | 0.78 | AKR1C3 (0.50) | NOTUMFAAHGRM7P2RX7 | |
| SCHEMBL30599788 | 0.78 | FAAH (0.46) | MTNR1AMTNR1BFAAHGRM7P2RX7 | |
| SCHEMBL22785039 | 0.77 | MTNR1A (0.53) | MTNR1AMTNR1BNOTUMFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118026995-A | Dihydrotriazole aromatization precursor and application thereof in deacylating and arylating reaction of ketone | 国科大杭州高等研究院 | 2024-05-14 | — | — | CN | claimed |
| CN-101775041-B | 2-acyl 1,3-indane dione silver compound with stable organic phosphine, preparation method and application thereof | UNIV NANJING AERONAUTICS | 2012-01-11 | — | — | CN | claimed |
| CN-118206514-A | Reaction method for preparing olefin by deacylation of visible light induced ketone | 国科大杭州高等研究院 | 2024-06-18 | — | — | CN | disclosed |
| CN-118026995-A | Dihydrotriazole aromatization precursor and application thereof in deacylating and arylating reaction of ketone | 国科大杭州高等研究院 | 2024-05-14 | — | — | CN | disclosed |
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-12-14 | — | — | US | disclosed |
| CN-117186010-A | Synthesis method of atimetazole hydrochloride | 厦门欧瑞捷生物科技有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-112225700-B | Preparation method of atemezole | 湖南新合新生物医药有限公司 | 2023-11-17 | — | — | CN | disclosed |
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-10-12 | — | — | US | disclosed |
| US-11673879-B2 | Substituted pyrimidines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230016922-A1 | VISIBLE-LIGHT MEDIATED ORGANOPHOTOREDOX CATALYTIC DEUTERATION OF AROMATIC AND ALIPHATIC ALDEHYDES | NATIONAL INSTITUTES OF HEALTH | 2023-01-19 | — | — | US | disclosed |
| CN-112225700-A | Preparation method of altimezole | 湖南新合新生物医药有限公司 | 2021-01-15 | — | — | CN | disclosed |
| EP-1361219-A1 | Herbicidal indanylalkylamino-1,3,5-triazines, process for their preparation, compositions thereof, and their use as herbicides and plant growth regulators | Bayer CropScience GmbH (DE) | 2003-11-12 | — | — | EP | disclosed |
| US-20020025965-A1 | Antiserotonine agents | ADIR ET COMPAGNIE (FR) | 2002-02-28 | — | — | US | disclosed |
| CN-1337395-A | Novel acardite compound, its preparation method and medicinal composition containing said compound | SERVIER LAB (FR) | 2002-02-27 | — | — | CN | disclosed |
| EP-1170288-A2 | Diphenylureum derivatives and their use as alpha2/5-HT2c antagonists | LES LABORATOIRES SERVIER (FR) | 2002-01-09 | — | — | EP | disclosed |
| EP-0310745-B1 | SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR PREPARATION AND USE | ORION-YHTYMÄ OY (FI) | 1993-01-27 | — | — | EP | disclosed |
| EP-0183492-B1 | SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR PREPARATION AND USE | Farmos-Yhtyma Oy (FI) | 1989-11-15 | — | — | EP | disclosed |
| EP-0310745-A2 | Substituted imidazole derivatives and their preparation and use | ORION-YHTYMÄ OY (FI) | 1989-04-12 | — | — | EP | disclosed |
| US-4689339-A | 4-dihydroinden-2-yl-, 4-tetrahydronaphth-2-yl-, and 4-dihydrobenzofuran-2-ylimidazoles, useful to block α2 -adrenergic receptors | FARMOS YHTYMA OY (FI) | 1987-08-25 | — | — | US | disclosed |
| EP-0183492-A1 | Substituted imidazole derivatives and their preparation and use | Farmos-Yhtyma Oy (FI) | 1986-06-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020025965-A1 | Antiserotonine agents | HTR2C, HTR3C, HTR3A | MTNR1A 79/4885MTNR1B 78/4885NOTUM 1350/4885 |
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | MYC, MYCBP, MYCBP2 | MTNR1A 2978/4885MTNR1B 2969/4885NOTUM 3825/4885 |
| US-11673879-B2 | Substituted pyrimidines and methods of use | ALK, TYMP, ENTPD5 | MTNR1A 3244/4885MTNR1B 2526/4885NOTUM 3791/4885 |
| US-20230016922-A1 | VISIBLE-LIGHT MEDIATED ORGANOPHOTOREDOX CATALYTIC DEUTERATION OF AROMATIC AND ALIPHATIC ALDEHYDES | AOX1, TDO2, TALDO1 | MTNR1A 1604/4885MTNR1B 2475/4885NOTUM 1022/4885 |
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | ALK, TYMP, ENTPD5 | MTNR1A 3244/4885MTNR1B 2526/4885NOTUM 3791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.